Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin injections in hip adductors with exercise for hereditary spastic paraplegia
NL-OMON42682Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in hereditary spastic paraplegia (HSP) comparing Botulinum toxin injection + exercises with Placebo injection + exercises (2 arms). Primary endpoints: Change in frontal-plane leg angle during bilateral stepping and Change in gait width during normal walking. Started Feb 2016; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on NL-OMON42682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42682.